EDSA Share Price | Edesa Biotech, Inc. Stock Analysis & Recommendation

Q: How big is Edesa Biotech, Inc.?

Market Cap: As of Jun 18, Edesa Biotech, Inc. has a market capitalization of 14.12 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Edesa Biotech, Inc. reported net sales of 0.00 million and a net profit of -5.84 million.Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 1.98 million and total assets of 3.94 million.

Q: What does Edesa Biotech, Inc. do?

Overview: Edesa Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing clinical-stage drugs for dermatological and gastrointestinal indications, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 14.12 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.89 Return on Equity: -41.60% Price to Book: 0.91Contact Details: Address: 100 Spy Crt, MARKHAM ON : L3R 5H6 Tel: 1 905 4751234 Website: https://www.edesabiotech.com/

Q: Is Edesa Biotech, Inc. overvalued or undervalued?

As of 6 February 2017, the valuation grade for Edesa Biotech, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. Based on the current analysis, the company appears to be overvalued. Key ratios include a price-to-book value of 0.83, an EV to EBIT of 0.16, and an EV to EBITDA of 0.17, all of which suggest that the company's valuation metrics are not supportive of a strong investment case.In comparison to its peers, Edesa Biotech's valuation is notably weaker, with NanoViricides, Inc. also classified as does not qualify but with a slightly worse EV to EBITDA of -2.0886, while Lisata Therapeutics, Inc. is rated risky with an EV to EBITDA of 0.2364. The negative return trends for Edesa Biotech, particularly a 54.34% decline over the past year compared to a 10.26% gain in the S&P 500, further reinforce the notion that the stock is not positioned favorably in the market.

Q: Is Edesa Biotech, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Edesa Biotech, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish RSI on the monthly timeframe. The daily moving averages also indicate a mildly bullish trend. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly and a bearish monthly outlook. The KST is bullish on the weekly but bearish on the monthly, while the OBV is mildly bullish on the weekly with no trend on the monthly.In terms of performance, Edesa Biotech has underperformed the S&P 500 over the past year, with a return of -45.50% compared to the S&P's 17.14%, and significantly underperformed over the last 3 and 5 years.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

81.78 k

Shareholding (Dec 2025)

FII

0.27%

Held by 12 FIIs

DII

98.59%

Held by 1 DIIs

Promoter

0.00%

How big is Edesa Biotech, Inc.?

22-Jun-2025

As of Jun 18, Edesa Biotech, Inc. has a market capitalization of 14.12 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -5.84 million over the latest four quarters. As of Sep 24, the company reported shareholder's funds of 1.98 million and total assets of 3.94 million.

View full answer

What does Edesa Biotech, Inc. do?

22-Jun-2025

Edesa Biotech, Inc. is a micro-cap biopharmaceutical company focused on developing clinical-stage drugs for dermatological and gastrointestinal conditions. As of March 2025, it reported a net profit loss of $2 million and has a market cap of $14.12 million.

View full answer

Who are in the management team of Edesa Biotech, Inc.?

22-Jun-2025

As of March 2022, the management team of Edesa Biotech, Inc. includes Independent Chairman Mr. Sean MacDonald, CEO Dr. Pardeep Nijhawan, Directors Mr. Frank Oakes, Dr. Lorin Johnson, Mr. Paul Pay, and Mr. Carlo Sistilli. They oversee the company's strategic direction and operations.

View full answer

Is Edesa Biotech, Inc. overvalued or undervalued?

25-Jun-2025

Edesa Biotech, Inc. is currently overvalued and classified as "does not qualify" due to significant financial concerns, with key ratios indicating weak valuation metrics and a 54.34% decline in stock price over the past year compared to a 10.26% gain in the S&P 500.

View full answer

Is Edesa Biotech, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Edesa Biotech, Inc. has shifted to a mildly bullish trend, supported by positive indicators like a bullish MACD and RSI, despite mixed signals from Bollinger Bands and underperforming the S&P 500 with a -45.50% return over the past year.

View full answer

Compare Edesa Biotech, Inc. with Similar Stocks

Mustang Bio, Inc.Lipocine, Inc.Aprea Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 43 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.86

Return on Equity

-60.20%

Price to Book

3.06

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

405.04%

6 Months

194.96%

1 Year

180.8%

2 Years

64.02%

3 Years

575.0%

4 Years

-69.88%

5 Years

-80.02%

Edesa Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-4.85%

EBIT Growth (5y)

-1.14%

EBIT to Interest (avg)

-11.77

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.89

Sales to Capital Employed (avg)

0.00

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

38.19%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.06

EV to EBIT

-3.67

EV to EBITDA

-3.72

EV to Capital Employed

16.13

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-439.11%

ROE (Latest)

-60.20%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (1.14%)

Foreign Institutions

Held by 12 Foreign Institutions (0.27%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -37.50% vs 5.88% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-1.90",
          "chgp": "-21.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.30",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-1.60",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2025 is -16.13% vs 26.19% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.80",
          "val2": "-6.80",
          "chgp": "-14.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.80",
          "val2": "0.70",
          "chgp": "14.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.20",
          "val2": "-6.20",
          "chgp": "-16.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.30

-1.90

-21.05%

Interest

0.00

Exceptional Items

0.10

0.30

-66.67%

Consolidate Net Profit

-2.20

-1.60

-37.50%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -37.50% vs 5.88% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.80

-6.80

-14.71%

Interest

0.00

Exceptional Items

0.80

0.70

14.29%

Consolidate Net Profit

-7.20

-6.20

-16.13%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in year ended Sep 2025 is -16.13% vs 26.19% in Sep 2024

All Annual Results

Company CV

About Edesa Biotech, Inc.

Edesa Biotech, Inc.

Pharmaceuticals & Biotechnology

Edesa Biotech Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical-stage drugs for dermatological and gastrointestinal indications. Its lead product candidate, EB01, is an sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD). Its pipeline also includes EB02 and EB04. EB02, an sPLA2 inhibitor, is being developed as a treatment for patients with hemorrhoids disease (HD). EB04 is being developed for anal fissures. It is also focused on developing biologic drug candidates for therapeutic, prophylactic and diagnostic applications.

Company Coordinates

Company Details

100 Spy Crt , MARKHAM ON : L3R 5H6

Tel: 1 905 4751234

https://www.edesabiotech.com/

Registrar Details